Biologics in congenital ichthyosis: are they effective?

医学 红斑 观察研究 生活质量(医疗保健) 内科学 红皮病 皮肤病科 银屑病 阿纳基纳 回顾性队列研究 依那西普 鱼鳞病 先天性鱼鳞病 儿科 疾病 类风湿性关节炎 护理部
作者
J. Mazereeuw‐Hautier,Celine J. Granier,Á. Hernández‐Martín,Silvia Vendruscolo Milesi,Hélène Texier,M. Sévérino-Freire,N. Bellon,Christine Bodemer,Robert Gruber,E. Mahé,Fanny Morice‐Picard,Katariina Hannula-Jouppi,Jenny E Murase,S. Barbarot,Eran Cohen‐Barak,Mauricio Torres Pradilla,Anna L. Bruckner,Moise L. Levy,Mark Jean Aan Koh,M. Masson Regnault,Vanya Rossel,C. Chiavérini,Lisa M. Arkin,Hagen Ott,Cristina Has,Kira Süβmuth,Antoni Gostyński,Jason Shourick,Amy S. Paller
出处
期刊:British Journal of Dermatology [Wiley]
标识
DOI:10.1093/bjd/ljae420
摘要

Abstract Background Congenital ichthyoses (CI) comprise a heterogeneous group of genetic diseases requiring lifelong treatment and having a major effect on quality of life. Conventional treatments reduce scaling and skin discomfort; however, they usually have little or no effect on erythema and pruritus. The identification of cytokine alterations in CI raised the possibility of repurposing available biologics. Several case reports in the literature report successes using different biologics. Objective We aimed to report the effects of biologics in real life. Methods This was a retrospective, observational, international multicenter study of patients with CI treated with at least one biologic for a minimum of 3 months. The effect of the biologics was evaluated using an Investigator Global Assessment-Change (IGA-C) scale. A comprehensive literature search was performed in parallel. Results A total of 98 patients were included, with a mean age of 19.7 years and both sexes equally represented. Patients with Netherton syndrome (NS) or congenital ichthyosiform erythroderma (CIE) represented the majority of patients (30% and 21.4%, respectively). Most patients (84.7%) had a severe or very severe form of CI. The most frequently used biologics were inhibitors targeting interleukin-17 (IL-17), IL-12/IL-23, or the IL-4 receptor. The mean duration of treatment was 22+20.1 months. There were 45 responders (45.9%), including 18 patients (18.3%) who were good responders; all had an erythrodermic CI subset and received one of the three main biologics. In 2 NS and CIE, IL-12/IL-23 and IL-4 receptor inhibitors tended to be most effective. Review of the literature revealed a shorter mean duration of use of biologics (11.5+8.5 months) and higher percentage of responders (85.7%), suggesting reporter bias. Conclusion This series identified subsets of CI that may respond to biologics and will aid in designing future clinical trials of biologics for CI.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Hello应助饱满的曼寒采纳,获得10
1秒前
1秒前
1秒前
张张张发布了新的文献求助30
2秒前
Lucas应助He采纳,获得10
2秒前
汉堡包应助牧云采纳,获得10
2秒前
2秒前
小阿波发布了新的文献求助30
5秒前
Simon发布了新的文献求助10
6秒前
葵魁发布了新的文献求助10
6秒前
Guoqiang发布了新的文献求助10
7秒前
紫腚能行发布了新的文献求助10
7秒前
Bella完成签到,获得积分10
7秒前
呵呵哒发布了新的文献求助10
8秒前
9秒前
HY完成签到,获得积分10
9秒前
mushrooms119完成签到,获得积分20
12秒前
苏七完成签到,获得积分10
12秒前
ajhs完成签到,获得积分10
13秒前
领导范儿应助伤心女大采纳,获得10
13秒前
斯文败类应助quanshijie采纳,获得10
13秒前
sam关闭了sam文献求助
14秒前
kk发布了新的文献求助50
14秒前
17秒前
17秒前
lll完成签到,获得积分10
20秒前
无花果应助ZHDG采纳,获得30
20秒前
吃点红糖馒头完成签到 ,获得积分10
20秒前
21秒前
laj发布了新的文献求助10
22秒前
有魅力的大船完成签到,获得积分10
22秒前
22秒前
张张张完成签到,获得积分20
24秒前
24秒前
24秒前
Leach完成签到 ,获得积分10
25秒前
25秒前
25秒前
8R60d8应助yanghq13采纳,获得20
27秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Genera Insectorum: Mantodea, Fam. Mantidæ, Subfam. Hymenopodinæ (Classic Reprint) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3083106
求助须知:如何正确求助?哪些是违规求助? 2736348
关于积分的说明 7540888
捐赠科研通 2385732
什么是DOI,文献DOI怎么找? 1265111
科研通“疑难数据库(出版商)”最低求助积分说明 612929
版权声明 597702